Co-Authors
This is a "connection" page, showing publications co-authored by ANAIS MALPICA and KWONG K WONG.
Connection Strength
1.269
-
Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. J Transl Med. 2022 12 17; 20(1):606.
Score: 0.228
-
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol. 2022 06; 165(3):560-567.
Score: 0.217
-
Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations. Sci Rep. 2020 11 26; 10(1):20678.
Score: 0.198
-
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol. 2013 Dec; 231(4):449-56.
Score: 0.122
-
The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol. 2011 Oct; 123(1):13-8.
Score: 0.103
-
The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol. 2011 Jun; 35(6):904-12.
Score: 0.102
-
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010 Oct; 177(4):1611-7.
Score: 0.097
-
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol. 2009 Sep; 22(9):1243-50.
Score: 0.089
-
Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol. 2007 Oct; 26(4):404-9.
Score: 0.079
-
Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015 Aug 20; 33(24):2675-82.
Score: 0.034